Cerebral: The Mental Health Telehealth Company That Flooded Social Media With ADHD Ads While Prescribing Stimulants Under Inadequate Clinical Safeguards

Cerebral Inc., a mental health telehealth company that offered ADHD evaluation and treatment as a core service alongside therapy and medication management, was charged with using deceptive marketing that misrepresented the clinical rigor of its ADHD evaluation and prescribing process while its subscription business model created financial incentives that regulators found were misaligned with responsible clinical practice — specifically, the incentive to continue prescribing controlled substance stimulants to maintain subscription revenue regardless of whether ongoing prescribing was clinically appropriate for the individual patient.DOCUMENTED

Cerebral grew rapidly during the COVID-19 pandemic, when telehealth expansion and remote work created both opportunity for digital mental health services and a surge in consumers seeking ADHD assessment and treatment. The company used social media advertising heavily, with campaigns that featured content about ADHD symptoms in ways that critics argued were designed to maximize self-identification rather than to help genuinely impaired individuals find appropriate care. The intersection of demand generation marketing, subscription revenue model, and controlled substance prescribing created a combination that attracted regulatory scrutiny from multiple directions simultaneously.DOCUMENTED

The ADHD Marketing Strategy

Cerebral's digital advertising campaigns — appearing extensively on TikTok, Instagram, and Facebook — featured content about ADHD symptoms and the improvement that treatment could bring. The advertising format, which regulators examined closely, presented symptom descriptions in ways that were broad enough to describe common experiences — difficulty concentrating, restlessness, forgetfulness — without the clinical context that would help a consumer distinguish between the normal variability in attention and focus that most people experience and the persistent, impairing pattern that constitutes clinical ADHD. The advertising drove a large volume of consumers toward Cerebral's ADHD assessment service, many of whom regulators found did not have clinical ADHD.DOCUMENTED

The marketing claims about the rigor and comprehensiveness of Cerebral's ADHD assessment process were a separate area of concern. Cerebral represented to consumers that its evaluation process would provide a thorough, clinically rigorous ADHD assessment — implying a standard of clinical care comparable to in-person psychiatric evaluation. Regulators found that the assessment processes Cerebral's prescribers used in practice were often less comprehensive than represented, with some evaluations relying primarily on patient-reported symptom checklists without the collateral history, behavioral observation, or diagnostic differentiation that clinical standards for ADHD diagnosis recommend.DOCUMENTED

The Subscription Model and Clinical Incentives

Cerebral's revenue depended on subscribers remaining enrolled — each subscriber who continued their medication management subscription generated recurring monthly revenue, while cancellations reduced revenue. For a patient taking a controlled substance stimulant medication, continuing the subscription was linked to continuing the prescription: without the subscription, the patient could not obtain prescription refills through Cerebral's system. This created a dependency structure in which patients who wanted to continue their medication had an incentive to continue their subscription, and Cerebral had a financial incentive to support that continuation regardless of whether ongoing prescribing was clinically justified.REVIEWED

Regulators found that prescriber compensation structures at Cerebral reinforced this dynamic — rewarding throughput and subscription continuation in ways that were not aligned with clinical best practices that would sometimes call for reducing or stopping medication, referring to in-person care, or delaying prescribing pending additional diagnostic workup. When financial incentives systematically favor continuing prescriptions over making the clinical determination appropriate to each patient's situation, the prescribing process is no longer purely clinical — it has been influenced by business model considerations in ways that compromise patient care.DOCUMENTED

Cerebral's marketing drove consumers toward ADHD diagnosis and stimulant prescriptions by describing symptoms broadly enough to resonate with nearly anyone — while the subscription model's financial structure favored keeping those patients on prescriptions and paying monthly fees.

Consumer Harm

The consumer harm in the Cerebral case includes both patients who were prescribed stimulant medications without adequate clinical evaluation — exposing them to the risks of stimulant use without the benefit of a genuine ADHD diagnosis that would make those risks clinically justified — and patients who were deceived about the quality of the clinical service they were receiving when they subscribed. Patients who believed they were receiving rigorous ADHD evaluation and appropriate medication management were receiving a service that did not meet the clinical standards Cerebral represented.DOCUMENTED

Patients who received ADHD diagnoses and stimulant prescriptions through Cerebral should discuss their treatment history with a qualified in-person provider to evaluate whether the diagnosis and prescribing were appropriate for their individual clinical presentation. Patients who continue to take stimulant medications initially prescribed through Cerebral should ensure they have an ongoing relationship with a qualified prescriber who has conducted an adequate evaluation. Individuals who enrolled in Cerebral's subscription based on misrepresentations about the clinical rigor of its services and who suffered harm as a result are encouraged to contact Watchdog Journal at /tips.REVIEWED

Evaluating Telehealth Mental Health Services

Consumers who are considering telehealth mental health services — particularly for services that might result in controlled substance prescriptions — should evaluate the platform's clinical standards carefully before enrolling. Questions to ask any telehealth mental health provider include: What credentials do the prescribing clinicians hold, and are they licensed in the patient's state? What is the evaluation process for diagnosing conditions that would be treated with controlled substances, and does it include a comprehensive clinical assessment rather than just a symptom checklist? How does the company's compensation model for prescribers account for clinical quality rather than just patient volume? Will the provider share clinical notes and treatment history with the patient's other healthcare providers? Telehealth has expanded access to mental health care in genuinely beneficial ways — the concern raised by the Cerebral case is not with telehealth mental health care generally but with specific business models that prioritize subscription revenue in ways that can compromise clinical judgment about when and how long to prescribe controlled substances.

Have documents relevant to this story? Reach us through our tips channel.